In preclinical mouse models, CCL21 was shown to facilitate antitumor activity via recruiting and colocalizing NK cells, DCs, and T cells in tumors, and it was supported that anti-PD-1 administered in combination with CCL21-DC tumor antigen therapeutic vaccines eradicated lung cancer [49]. This evidence concerns the gene PDCD1 and lung carcinoma.